Back to today’s briefing

Story perspectives

5th Circuit Blocks Telehealth Abortions, Limits Access Nationwide

5/2/2026

50 3 Full Breakdown

Left

Court Blocks Telehealth

The ruling threatens telehealth abortions for rural, low-income and disabled patients nationwide.
A panel of the 5th Circuit Court of Appeals ordered mifepristone be prescribed in clinics, overturning FDA’s 2023 telemedicine rule.
The ruling was dubbed a jolt to policy since the 2022 Roe v. Wade reversal.
Guttmacher Institute Kelly Baden warned decision will restrict access even in states with abortion rights.

Right

Court Limits Mifepristone

The 5th U.S. Circuit Court of Appeals rebuked the FDA for ending adverse-event reporting on mifepristone.
A federal appeals court ordered that mifepristone be prescribed only at clinics, halting nationwide mail-order distribution.
Students for Life President Kristan Hawkins called the nationwide ruling a victory for the unborn.
Louisiana Attorney General Liz Murrill said the restriction protects the state’s abortion ban.

History

Historical Context

The 1973 Supreme Court ruling in Roe v. Wade, decided 7-2, protected a federal right to first-trimester abortion. That right endured until the Court’s 2022 Dobbs decision overturned Roe, reviving state-level restrictions. Now the 5th U.S. Circuit Court of Appeals is limiting mifepristone distribution, reflecting the post-Dobbs legal push to curtail nationwide reproductive-health access.

1 of 3

Court Blocks Telehealth

The ruling threatens telehealth abortions for rural, low-income and disabled patients nationwide.
A panel of the 5th Circuit Court of Appeals ordered mifepristone be prescribed in clinics, overturning FDA’s 2023 telemedicine rule.
The ruling was dubbed a jolt to policy since the 2022 Roe v. Wade reversal.
Guttmacher Institute Kelly Baden warned decision will restrict access even in states with abortion rights.

1 / 3